bioRxiv Science⌕ Search

Biology subjects

Festa, J.

Publications and source records attributed to Festa, J..

2 recordsLinked to original sources

Defining the Vascular Niche of Human Adipose Tissue Across Metabolic Conditions

IntroductionAdipose tissue homeostasis depends on a healthy vascular network. Vascular malfunction is a hallmark of obesity1, and vascular endothelial dysfunction, in particular, accelerates metabolic diseases, including obesity and diabetes. Single-cell transcriptomics studies have mapped the cellular landscape of human white adipose tissue (WAT)2-8. However, the vascular niche remains relatively undefined9, especially regarding its heterogeneity, function, and role in metabolic disease. To address this gap, we created a single-cell transcriptome atlas of human subcutaneous adipose tissue (SAT), comprising nearly 70,000 vascular cells from 65 individuals. We characterized seven canonical adipose tissue endothelial cell (AdEC) subtypes and identified a distinct heterogenous population, here referred to as sub-AdECs. Sub-AdECs exhibit gene signatures characteristic of multiple cell types, including mesenchymal, adipocytic, and immune, suggesting they possess diverse properties and identities. Through computational analyses and whole-mount imaging, we validated the occurrence of sub-AdECs and show that these cells likely arise through endothelial-mesenchymal transition (EndMT), the modulation of which limits obesity-associated adipose tissue inflammation and fibrosis. Furthermore, we compared the transcriptomes of vascular cells from individuals living with or without obesity and type 2 diabetes and find metabolic disease-associated inflammatory and fibrotic transcriptomic patterns. The atlas and accompanying analyses establish a solid foundation for investigations into the biology of the adipose tissue vascular niche and its contribution to the pathogenesis of metabolic disease.

cell biology↗

2-bromo-2',5'-dihydroxychalcone analogue Inhibits Endothelial Migration by Targeting VEGF-induced ERK 1/2 Phosphorylation

Angiogenesis, the process of new blood vessel formation, is characterized by three essential hallmarks: endothelial proliferation, migration, and differentiation. Each is integral in angiogenesis related diseases, especially cancer. With drug efficacy stagnated due to acquired drug resistance and off target side effects, the need for combinatorial therapy is ever more present. To identify new compounds that could aid current antiangiogenic therapies, we report the preliminary mechanistic evaluation of a 2-bromo-25-dihydroxychalcone analogue and its antimigratory effects on endothelial cells. After the synthesis and validation of the 2-bromo-25-dihydroxychalcone analogue (AH9), its effect was tested in vitro using human umbilical vein endothelial cells (HUVEC). Initial investigations into 2-bromo-25-dihydroxychalcone effect in vitro was conducted with a cell proliferation assay including MTT, afterward endothelial migration was measured with the scratch assay in subsequent functional studies. For mechanistic evaluation, vascular endothelial growth factor (VEGF) induced ERK phosphorylation using western blot was implemented. AH9 inhibited VEGF-induced ERK [1/2] phosphorylation similar to that of known antiangiogenic drug Sorafenib at all three concentrations 100 M (46%, p = 0.003), 30 M (64%, p = 0.0002) and 10 M (91%, p = 0.0001). In a scratch assay model, whilst sorafenib at 3 M was not able to limit migration after 8-hr compared to an untreated control (p = 0.0978), AH9 did (17.41%, p = 0.0079). Furthermore, AH9 was able to inhibit ERK [1/2] phosphorylation in a concentration dependent manner 100 M (46%, p = 0.003), 30 M (64%, p = 0.0002) and 10 M (91%, p = 0.0001) compared to the VEGF control. These preliminary findings support that AH9 could be exerting antimigratory effects through the inhibition of the VEGF induced MAPK/ERK pathway. This forms the foundation for further studies to explore chalcone analogues in hope to aid current antiangiogenic therapeutic strategies as potential angiogenic inhibitors.

pharmacology and toxicology↗